Antibodies against the extracellular virion (EV, EEV) form of vaccinia virus are an important component of protective immunity in animal models and likely contribute to the protection of immunized humans against poxviruses. Using fully human monoclonal antibodies we now show that the protective attributes of the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent on effector functions. By switching Fc domains of a single mAb, we definitively show that neutralization in vitro-and protection in vivo in a mouse model-by the human anti-B5 IgG is isotype dependent, thereby demonstrating that efficient protection by these antibodies is not simply dependent on binding an appropriate vaccinia virion antigen with high affinity, but in fact requires antibody effector function. Complement components C3 and C1q, but not C5, were required for neutralization. We also demonstrate that human mAbs against B5 can potently direct complement dependent cytotoxicity (CDC) of vaccinia infected cells. Each of these results were then extended to the polyclonal human antibody response to the smallpox vaccine. A model is proposed to explain the mechanism of EV neutralization. Altogether these findings enhance our understanding of the central protective activities of the smallpox vaccine in immunized humans.
INTRODUCTION
The smallpox vaccine, live vaccinia virus (VACV), is frequently considered the gold standard of human vaccines, and has been enormously effective in preventing smallpox disease.
The smallpox vaccine led to the worldwide eradication of the disease via massive vaccination campaigns in the 1960s and 1970s, one of the greatest successes of modern medicine (30, 31) .
However, despite the efficacy of the smallpox vaccine, the mechanisms of protection remain unclear. Understanding those mechanisms is key for developing immunologically sound vaccinology principles that can be applied to the design of future vaccines to other infectious diseases (3, 101) .
Clinical studies of fatal human cases of smallpox disease (variola infection) showed that neutralizing antibody titers were either low or absent in patient serum (24, 68) . In contrast, neutralizing antibody titers to VACV MV virion were correlated with protection of vaccinees against smallpox (68) . Vaccinia Immune Globulin (VIG, polyclonal antibodies) is a promising treatment against smallpox (47) , as it was able to reduce the number of smallpox cases ~80% among variola exposed individuals in four case controlled clinical studies (43, 47, 52, 53, 69) . In animal studies, neutralizing antibodies are crucial for protecting primates and mice against pathogenic poxviruses (3, 7, 17, 21, 27, 35, 61, 66, 85) .
The specificities and the functions of protective anti-poxvirus antibodies have been areas of intensive research, and the mechanics of poxvirus neutralization have been debated for years.
There are several interesting features and problems associated with the antibody response to variola and related poxviruses, including the large size of the viral particles and the varying assays have indicated that antibodies generated against B5 are primarily responsible for neutralization of VACV EV (5, 83) . Recently, Chen at al., have generated chimpanzee-human fusion mAbs against B5 and have shown that the mAbs can protect mice from lethal challenge with virulent VACV (17) . We have recently reported, using murine monoclonal antibodies, that neutralization of EV is highly complement dependent, and the ability of anti-B5 mAbs to protect in vivo correlated with their ability to neutralize EV in a complement dependent manner (7) .
The focus of the study reported here was to elucidate the mechanisms of EV neutralization, focusing on the human antibody response to B5. Our overall goal is to understand underlying immunobiological and virological parameters that determine the emergence of protective antiviral immune responses in humans.
MATERIALS AND METHODS
Ethics Statement. Informed consent was obtained for all human work, and the human studies were Institutional Review Board (IRB) approved. All animal experiments were conducted using Institutional Animal Care and Use Committee approved animal protocols.
Sera. Plasma samples from a non-immune donor and a Dryvax® immunized donor at 4 weeks
post-vaccination were stored at -80°C. Rabbit-anti L1 sera were generated by immunizing two rabbits with recombinant L1 protein as described in (7) . Human plasma and rabbit sera were heat inactivated prior to use to eliminate complement activity (56°C, 30 and 60 min respectively).
Human vaccinia immune globulin (50 mg/ml VIG; Cangene Corp., Winnipeg, Canada) was stored at -80 °C.
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Mice. KM mice ™ were generated by cross breeding double transchromosomic mice and transgenic mice (50, 97) . KM mice possess the human chromosome fragments containing the entire human immunoglobulin heavy chain locus and the YAC transgene for 50% of the human immunoglobulin kappa light chain locus. KM mice are engineered to neither express endogenous immunoglobulin heavy chain (µMT) nor kappa light chain (κ-/-). KM mice are used to obtain human monoclonal antibodies. Female BALB/cByJ mice (Jackson Laboratory) 8-12 weeks of age were used in all in vivo protection experiments.
Viruses. VACV WR (Western Reserve) was used unless otherwise stated. VACV IHDJ was obtained from Stuart Isaacs (U. Penn). Recombinant VACV WR B5-GFP (VACV/B5-GFP) was obtained from Dr. Bernard Moss (NIH) (104) .
VACV MV stocks were grown on HeLa cells in D-10 (DMEM + 10% FCS + pen/strep/glutamine) as described previously (7) . Fetal calf serum (FCS) used in all experiments was heat inactivated (56 °C, 30 min) prior to use to eliminate complement activity. Purified VACV WR , VACV/B5-GFP, or VACV IHDJ stocks were made via centrifugation through a sucrose cushion as described previously (7) . Virus was stored at -80°C.
EV stocks of VACV were prepared as previously described (7) . Briefly, HeLa cells were used and the medium containing EV was harvested at 2 days after infection. Virus was isolated by centrifugation (450g, 8 min) twice to remove cells. Clarified supernatant was used immediately or stored at 4 °C for a maximum of 3-4 weeks (1). EV VACV WR stocks (~5 x 10 9 against B5 ([h101 IgG1, h102 IgG1, or h106 IgG4] 10 µg/ml, final concentration) in D-10 medium were used in the absence or the presence of 10 % of normal human serum complement (NHS) or C1q-, C3-, fB-, or C5-depleted human sera (QUIDEL, San Diego, CA). For Figure 6D , C1q purified protein (10 µg/ml, QUIDEL, San Diego, CA) was used. 100 µl mAb plus complement samples were incubated in an equal volume of EV VACV WR (1:100 dilution, + 1:50 final concentration anti-L1 Ab) for 30 min at 37 o C, 5% CO 2 . EV plaque assays were performed as described above. Fig. 1 ).
EV neutralization in vitro by human anti-B5 mAbs was complement dependent and protection in vivo was affinity and isotype dependent.
Hybridomas selected in the primary rB5 ELISA screening were tested for EV neutralization potency. Initially, we utilized the most commonly used in vitro EV neutralization assay, comet tail inhibition, which measures a reduction of VACV IHDJ spread in culture supernatant (36, 60) . This assay required high antibody concentrations for effective virus neutralization (20 µg/ml). Out of nine top anti-B5 human antibodies tested in this assay, only a single candidate (h101, Fig. 2A ) showed strong inhibition, and two candidates (h102, Fig. 2A; and h108, data not shown) showed partial inhibition. VIG (human vaccinia immune globulin) or plasma from a human smallpox vaccinee that had high anti-B5 IgG titers (data not shown)
showed complete inhibition of comet tail formation, while control human plasma or IgG1 or IgG3 mAb had no inhibitory effect on comet tail formation ( Fig. 2A , and data not shown).
Direct EV neutralization with human mAbs alone was poor, with maximal neutralization of ~20% even at high antibody concentrations (Figs. 2B, 4B, 4D ). This was consistent with the literature showing the difficulty of neutralizing EV (7, 16, 17, 34, 36, 66, 67, 98, 99) . Recently, we have developed a complement-dependent EV neutralization assay that is convenient, provides a high signal-to-noise ratio, and has biological relevance as it accurately predicted protective capacities of murine mAbs against lethal vaccinia virus challenges in vivo (7) . We refer to this complement dependent neutralization assay as a "physiological EV neutralization assay". The physiological EV neutralization assay was applied to screen these B5-specific human IgGs. This assay revealed four strongly neutralizing antibodies: h101, h102, h104 and h105 ( Fig. 2C ) and one antibody with partial activity (h108). Neutralization was only observed among the high affinity mAbs (clone h101, h102, h104, or h105) and not the lower affinity mAbs (clone h103 or h109). Representative high affinity monoclonal h102 potently neutralized EV in a dosedependent manner, with a 50% plaque neutralization titer (PRNT 50 ) of 27 ng/ml (Fig. 2D ).
Neutralization also correlated with isotype, as IgG1 and IgG3 antibodies neutralized Our findings show that mAb affinity, concentration, and isotype can be correlated with virus neutralization activity in vitro. Only complement fixing mAbs with high affinity had the ability to neutralize vaccinia EV in the presence of complement.
From the physiological EV neutralization assay we predicted that only high affinity anti-B5 mAbs of IgG1 or IgG3, but not IgG4, isotype would be protective in vivo. To test these predictions, we first tested high and low affinity anti-B5 IgG1 mAbs (h102 and h109 respectively) for in vivo efficacy using the VACV WR intranasal challenge model in mice. This is an established small animal model for testing vaccinations and therapeutic treatments related to human inhalation smallpox (6, 7, 17, 66, 109) . Here, mice were treated with individual human anti-B5 mAbs followed by a lethal dose of VACV WR via intranasal challenge. As shown in Figure 3A -C, mice treated with low affinity h109 human IgG1 mAb lost weight after infection similarly to untreated mice ( Fig. 3A -B) and died by day 8 post-infection ( Fig. 3C ). In contrast, the high affinity h102 human IgG1 mAb was highly protective (P < 0.004, h102 vs. h109, P < 0.003, h102 vs. PBS. Fig. 3B ). All h102 treated mice survived (P < 0.02, h102 vs. PBS. P < 0.004, h102 vs. h109. Fig. 3C ). Furthermore, in separate challenge experiments, we tested a high affinity h106 IgG4 that had shown no in vitro physiological EV neutralization activity. Anti-B5
h106 IgG4 was not protective in vivo (P < 0.005, h106 vs. h101. P >> 0.05, h106 vs. PBS. Fig.   3D ). Therefore, the physiological neutralization assay is a good predictor of efficacy of human antibodies in vivo, and the protective capacity of human antibody responses against vaccinia EV is affinity and isotype dependent, reflecting the importance of complement.
EV neutralization in vitro and protection in vivo by isotype switched human anti-B5 mAbs.
To formally test the importance of the Fc domain in VACV EV neutralization, we switched the isotype of human anti-B5 monoclonal h104 from IgG3 to either IgG1 or IgG4 by genetic engineering. These three isotypes of mAb h104 displayed comparable high affinity binding to B5 ( Complement can be activated via three pathways: classical, alternative and lectin. Given that complement fixing human IgG isotypes were required for VACV EV neutralization, we examined which complement factors were involved by using C1q-, C3-, C5-and fB-depleted human sera. Experiments revealed a strong dependence on C1q (71% VACV EV neutralization activity loss) and C3 (77% loss), whereas absence of fB or C5 had little effect on EV neutralization ( anti-B5 required C1q (Fig. 6A) , however anti-B5 h101 IgG1 was unable to neutralize EV VACV when supplemented with purified C1q protein alone (P < 0.02, C1q protein + h101 vs. NHS + h101. Fig. 6D ). The addition of purified C1q to C1q-depleted human sera fully restored the neutralization activity, demonstrating that the purified C1q protein was fully active (P < 0.006, C1q-depleted + C1q protein + h101 vs. C1q-depleted + h101. Fig. 6D ). These experiments suggest that the primary mechanism of neutralization was opsonization via coating of the EV particles with antibody bound to C1q and subsequent activation and fixation of complement C3, sterically preventing EV from binding to cells (See Discussion and Figure 10 ). Given that C5
was dispensable (Fig. 6A) , complement mediated lysis of EV viral particles (virolysis) did not appear to be a major pathway of neutralization by human anti-B5 antibodies.
Complement-fixing B5 antibodies mediated complement dependent cytotoxicity (CDC)
destruction of VACV infected cells.
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Complement can function in multiple ways, and we recently showed that murine anti-B5
antibodies are effective at directing complement mediated destruction of VACV infected cells, utilizing the membrane attack complex (7) . EV are secreted from the plasma membrane and B5
is expressed on the surface of VACV infected cells (7, 18, 49, 75, 93, 104) . Human anti-B5 mAb h101 efficiently labeled B5 on the surface of VACV infected cells (Fig. 7A-B) . We examined the ability of h104 IgG1, IgG3, or IgG4 to mediate complement dependent cell killing of VACV infected cells. Treatment of infected cells with complement alone had no effect (Fig. 7C ).
Treatment with h104 IgG1, IgG3, or IgG4 alone also had no effect ( Fig. 7C-F There is evidence that the ability of VIG to neutralize EV is largely due to the presence of anti-B5 IgG (5, 83) . As shown in Figure 8A , VIG alone has only a modest EV neutralization activity in vitro even at very high concentration (0.5 to 1 mg/ml). However, neutralization by VIG was vastly improved by the presence of complement (Fig. 8A ). Comparable EV neutralization activity was obtained using plasma from human smallpox vaccinees (Fig. 8B ).
Non-immune human plasma had no activity (Fig. 8B ).
VIG was very effective at lysing VACV infected cells in vitro in the presence of complement (Fig. 9A, D) . Plasma from individual human vaccinees was also very efficient at killing VACV infected cells in the presence of the complement (Fig. 9B, E) . Together, these results demonstrate the physiological relevance of this study, and that significant EV neutralization activity (>90%) by human antibodies is only observed in the presence of complement.
Discussion
It EV neutralization has been a conundrum for decades. While it has been demonstrated in multiple studies that antibodies against B5 antigen protect against a lethal intranasal VACV challenge in animal models (7, 17, 34, 36, 66, 91) and antibodies against B5 are present in human vaccinees (5, 22, 62, 82, 83) , the mechanism(s) of protection have been unknown.
Recently we clarified several key features of protective murine anti-B5 antibodies (7) . The relationship between EV neutralization by human monoclonal and polyclonal antibodies and protection in vitro and in vivo remained unclear. We generated a new panel of human anti-B5 monoclonal antibodies to facilitate these studies. These human mAbs can also potentially be used as human therapeutic agents for protection against vaccinia, monkeypox, or variola. 
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Interestingly, we observed that human anti-B5 IgG1 mAb had an inhibitory effect on comet tail formation in vitro, while IgG3 and IgG4 anti-B5 mAbs had no effect on comet tails (data not shown). The comet tail reduction assay therefore appears to measure some complement fixation capacity, as well as affinity, and possibly other attributes of immunoglobulins such as an ability to block virion release (98) . (Fig. 10A) . We found that even high concentrations of anti-B5 IgG were insufficient to neutralize the virus (Fig. 4D) , indicating that the coating model is not applicable to the EV of poxviruses. We postulated that the coating model fails because EV escape direct neutralization by anti-B5 IgG binding because B5 protein is present at relatively low density on the surface of EV and direct occupancy of all B5 binding sites is insufficient to fully cover the surface of the virus (Fig. 10B) . Therefore, the neutralization activity of anti-B5 mAbs is observed only when complement is present (Fig. 10C) (Fig. 6 ). We propose in our neutralization model that C1q increases the footprint of the immunoglobulin, occupying a much larger surface area of the virion, sterically hindering infection (Fig. 10C) . Furthermore, covalent attachment of many C3b's to the virion obstructs binding to target cells (Fig. 10C ) (10, 79) .
Mechanism of neutralization
The EV neutralization model we propose (Fig. 10) , also posits that B5 is not essential for EV virion infectivity, as our data shows that saturating levels of anti-B5, presumably occupying all B5 proteins, still does not block the infectivity of EV (Figs. 4D, 10B ). This indicates that viral binding and entry can be mediated by other EV virion antigens or components. Human complement deficiencies are frequently associated with autoimmune diseases like systematic lupus erythematosus (SLE), arthritis, and others (11, 12, 38, 64, 102, 103) . There is evidence that human complement deficiencies also result in serious health problems after viral or (13, 32, 78) . Several reports now indicate that genetic deficiency of C1q in humans results in enhanced susceptibility to pathogens (15, 32, 96, 106) , and if individuals survive these infections they develop lupus-like autoimmune disease (12, 74, 80, 102, 103) .
Vaccinia virus encodes vaccinia complement control protein, VCP (C3L, WR025), which binds C3b and C4b (58, 59, 89) and can also form a covalent heterodimer with EV surface protein A56 (37, 100) . VCP is a known virulence factor of vaccinia (58) . VACV WR , which expresses VCP, was used in our in vitro and in vivo experiments. Therefore the inhibitory effects of VCP are only partial and can be overcome. The observation that VCP deleted VACV mutants have only a moderate loss of virulence is consistent with these findings (48) .
Protective anti-EV antibodies in vaccinees
The smallpox vaccine generates strong antibody responses to the EV form in immunized humans, and the antibody responses are mostly directed against B5, A33 and A56 viral proteins (5, 22, 25, 62, 82, 83) . Mice infected with VACV WR also generate strong antibody responses against multiple EV proteins, and A33 or B5 immunization can be protective in mice (7, 44, 45) .
The complement dependent EV neutralization findings using VIG or plasma from human smallpox vaccinees ( 
